65,437 trials
Influenza
Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against 3 Strains of Influenza Disease. — 26.7; 28.5; 28.6; 27.9 titers
Myopia
Primary: Pre-Lens Non-Invasive Tear Break-Up Time (PL-NITBUT) — 13.56; 12.0; 11.86 seconds
Heart Failure
Primary: Change in Serum Creatinine — -0.04; 0.23 mg/dL
Breast Cancer
Primary: Change in Blood Concentrations — 4.2; -0.03 ng/ml
Infections, Rotavirus
Primary: Number of Subjects With Severe Episode(s) of Rotavirus Gastroenteritis (RVGE) Caused by the Circulating Wild Type (WT) Strains — 21; 75 Participants
Heart Failure
Primary: False Positive Rate — 1.8; 1.49 departures from device threshold
Breast Cancer · Hot Flashes
Primary: Number of Daily Hot Flashes — 5; 4.5 daily hot flashes
Attention-Deficit/Hyperactivity Disorder
Primary: Time to First Response — 12.0; 21.0 Days — p==0.001
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
Hepatitis C, Chronic
Primary: Percentage of Participants With a Sustained Virologic Response 24 Weeks After Scheduled Completion of Treatment — 52; 57 percentage of participants — p=0.4557
Pain
Primary: Quality of Recovery 40 Score — 175; 157.5 units on a scale
Opioid Dependence · Opioid Withdrawal · Opioid Detoxification
Primary: Illicit Opioid Use as Determine by Urine Dipsticks — 13.64; 32.56 % of urines positive for opioids — p=0.035
Rheumatoid Arthritis
Primary: Mean Change From Baseline in Global Power Doppler Ultrasonography (PDUS) Score Assessing the Metacarpophalangeal (MCP) 2-5 Joints of Both Hands (LOCF Analysis) — -0.7…
Blood Pressure
Primary: Difference Between the B40 Monitor and Reference Device DINAMAP PRO1000 on NIBP Measurements — -1.4; -3.3; -3.7 mmHg
Type 1 Diabetes Mellitus · Dyslipidemia
Primary: Change in LDL-c From Baseline to 6 Months in Subjects With Type 1 Diabetes Taking Vytorin or Zocor. — -67; -6 mg/dl